Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Deloitte
QuintilesIMS
Teva
AstraZeneca
Daiichi Sankyo
McKesson
US Department of Justice

Generated: July 19, 2018

DrugPatentWatch Database Preview

Atovaquone - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for atovaquone and what is the scope of atovaquone patent protection?

Atovaquone
is the generic ingredient in five branded drugs marketed by Amneal Pharms, Apotex Inc, Paddock Llc, Glaxosmithkline Llc, Glenmark Generics, Mylan Pharms Inc, and Glaxosmithkline, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for atovaquone. Three suppliers are listed for this compound.
Pharmacology for atovaquone
Medical Subject Heading (MeSH) Categories for atovaquone

US Patents and Regulatory Information for atovaquone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-002 May 27, 2014 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline MALARONE PEDIATRIC atovaquone; proguanil hydrochloride TABLET;ORAL 021078-002 Jul 14, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Inc ATOVAQUONE atovaquone SUSPENSION;ORAL 209750-001 Oct 11, 2017 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for atovaquone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chubb
Julphar
Express Scripts
Deloitte
Chinese Patent Office
US Army
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.